JP5247705B2 - 抗細菌活性を持つ置換チエノピリドン化合物 - Google Patents
抗細菌活性を持つ置換チエノピリドン化合物 Download PDFInfo
- Publication number
- JP5247705B2 JP5247705B2 JP2009530510A JP2009530510A JP5247705B2 JP 5247705 B2 JP5247705 B2 JP 5247705B2 JP 2009530510 A JP2009530510 A JP 2009530510A JP 2009530510 A JP2009530510 A JP 2009530510A JP 5247705 B2 JP5247705 B2 JP 5247705B2
- Authority
- JP
- Japan
- Prior art keywords
- mono
- propylamino
- thieno
- ylamino
- carboxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 117
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 11
- -1 cyano, hydroxyl Chemical group 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 8
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- NNTYBKTXMKBRFA-UHFFFAOYSA-N 5-[3-[(6,8-dibromo-3,4-dihydro-2h-chromen-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(Br)=CC(Br)=C2OCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 NNTYBKTXMKBRFA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 5
- UDXHHFWPEQVZHL-UHFFFAOYSA-N 5-[3-[(8-bromo-6-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(Cl)=CC(Br)=C2NCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 UDXHHFWPEQVZHL-UHFFFAOYSA-N 0.000 claims description 5
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- ORJANCIYXUWLJI-UHFFFAOYSA-N 5-[3-[(6-bromo-8-chloro-3,4-dihydro-2h-chromen-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C1COC=2C(Cl)=CC(Br)=CC=2C1NCCCNC(N1)=CC(=O)C2=C1C=CS2 ORJANCIYXUWLJI-UHFFFAOYSA-N 0.000 claims description 4
- IEYWHUPJVADWAA-UHFFFAOYSA-N 5-[3-[(6-chloro-8-iodo-3,4-dihydro-2h-chromen-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(Cl)=CC(I)=C2OCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 IEYWHUPJVADWAA-UHFFFAOYSA-N 0.000 claims description 4
- YPNCSBUZKRLQLT-UHFFFAOYSA-N 5-[3-[(8-bromo-6-chloro-3,4-dihydro-2h-chromen-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(Cl)=CC(Br)=C2OCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 YPNCSBUZKRLQLT-UHFFFAOYSA-N 0.000 claims description 4
- PTCYZSXNRSQXRU-UHFFFAOYSA-N 5-[3-[(8-bromo-6-methylsulfanyl-3,4-dihydro-2h-chromen-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(SC)=CC(Br)=C2OCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 PTCYZSXNRSQXRU-UHFFFAOYSA-N 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- KXIYFUZJJDTUPW-UHFFFAOYSA-N 5-[3-[(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C12=CC(Br)=CC(Br)=C2NCCC1NCCCNC(N1)=CC(=O)C2=C1C=CS2 KXIYFUZJJDTUPW-UHFFFAOYSA-N 0.000 claims description 2
- LELAAFBXRNUHNO-UHFFFAOYSA-N 5-[3-[(6-bromo-8-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C1CNC=2C(Cl)=CC(Br)=CC=2C1NCCCNC(N1)=CC(=O)C2=C1C=CS2 LELAAFBXRNUHNO-UHFFFAOYSA-N 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 108010003060 Methionine-tRNA ligase Proteins 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 102000000362 Methionyl-tRNA synthetases Human genes 0.000 description 38
- 239000003112 inhibitor Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000003242 anti bacterial agent Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 239000003053 toxin Substances 0.000 description 13
- 231100000765 toxin Toxicity 0.000 description 13
- 108700012359 toxins Proteins 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000012010 growth Effects 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000003595 spectral effect Effects 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 238000010189 synthetic method Methods 0.000 description 9
- 241000193163 Clostridioides difficile Species 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 7
- 108010059993 Vancomycin Proteins 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 229960003165 vancomycin Drugs 0.000 description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 6
- 241000589562 Brucella Species 0.000 description 6
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- OFOMGGMKXLKLBS-UHFFFAOYSA-N 5-(3-aminopropylamino)-4h-thieno[3,2-b]pyridin-7-one;hydrochloride Chemical compound Cl.N1C(NCCCN)=CC(=O)C2=C1C=CS2 OFOMGGMKXLKLBS-UHFFFAOYSA-N 0.000 description 5
- NNTYBKTXMKBRFA-CQSZACIVSA-N 5-[3-[[(4r)-6,8-dibromo-3,4-dihydro-2h-chromen-4-yl]amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound N([C@@H]1CCOC2=C(Br)C=C(C=C21)Br)CCCNC(N1)=CC(=O)C2=C1C=CS2 NNTYBKTXMKBRFA-CQSZACIVSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 4
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- VCWYGOAHUQHTKV-UHFFFAOYSA-N C1=CC=C2NC(NCCCNC3=CCSC4=C(Br)C=C(C=C43)Br)=CC(=O)C2=C1 Chemical compound C1=CC=C2NC(NCCCNC3=CCSC4=C(Br)C=C(C=C43)Br)=CC(=O)C2=C1 VCWYGOAHUQHTKV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960003128 mupirocin Drugs 0.000 description 3
- 229930187697 mupirocin Natural products 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- XWKAVQKJQBISOL-UHFFFAOYSA-N 2-(phenylazaniumyl)propanoate Chemical compound OC(=O)C(C)NC1=CC=CC=C1 XWKAVQKJQBISOL-UHFFFAOYSA-N 0.000 description 2
- SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- VTFPYUHFWSVFQK-UHFFFAOYSA-N 5-(3-acetamidopropylamino)-7-oxo-4h-thieno[3,2-b]pyridine-6-carboxylic acid Chemical compound O=C1C(C(O)=O)=C(NCCCNC(=O)C)NC2=C1SC=C2 VTFPYUHFWSVFQK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 0 Cc(cc1*)cc2c1OCCC2NCCCNC(Nc1c2[s]cc1)=CC2=O Chemical compound Cc(cc1*)cc2c1OCCC2NCCCNC(Nc1c2[s]cc1)=CC2=O 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 210000000712 G cell Anatomy 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 229960000443 hydrochloric acid Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 description 1
- RYAUSSKQMZRMAI-YESZJQIVSA-N (S)-fenpropimorph Chemical compound C([C@@H](C)CC=1C=CC(=CC=1)C(C)(C)C)N1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-YESZJQIVSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- VUBNWCUYVMGHAL-UHFFFAOYSA-N 2-[3-[[3,5-dibromo-2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl]methylamino]propylamino]-1h-quinolin-4-one Chemical compound N1=CSC(CCOC=2C(=CC(Br)=CC=2Br)CNCCCNC=2NC3=CC=CC=C3C(=O)C=2)=C1C VUBNWCUYVMGHAL-UHFFFAOYSA-N 0.000 description 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical group C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 1
- AKXYKVHNZQCHMF-UHFFFAOYSA-N 3-amino-4-methylthiophene-2-carboxylic acid Chemical compound CC1=CSC(C(O)=O)=C1N AKXYKVHNZQCHMF-UHFFFAOYSA-N 0.000 description 1
- PXVZAKMJAWZMGF-UHFFFAOYSA-N 3-aminothiophene-2-carboxylic acid;hydrochloride Chemical compound Cl.NC=1C=CSC=1C(O)=O PXVZAKMJAWZMGF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- VXNDEDJEUROKHF-UHFFFAOYSA-N 5-(3-aminopropylamino)-4h-thieno[3,2-b]pyridin-7-one;dihydrochloride Chemical compound Cl.Cl.N1C(NCCCN)=CC(=O)C2=C1C=CS2 VXNDEDJEUROKHF-UHFFFAOYSA-N 0.000 description 1
- HYOBZFLPBXIJKC-UHFFFAOYSA-N 5-[3-[(6-bromo-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound C1CNC=2C(F)=CC(Br)=CC=2C1NCCCNC(N1)=CC(=O)C2=C1C=CS2 HYOBZFLPBXIJKC-UHFFFAOYSA-N 0.000 description 1
- YHUVALDGGSJQNJ-UHFFFAOYSA-N 5-[3-[[3,5-dibromo-2-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]phenyl]methylamino]propylamino]-4h-thieno[3,2-b]pyridin-7-one Chemical compound N1=CSC(CCOC=2C(=CC(Br)=CC=2Br)CNCCCNC=2NC=3C=CSC=3C(=O)C=2)=C1C YHUVALDGGSJQNJ-UHFFFAOYSA-N 0.000 description 1
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 description 1
- NPVIVRRXGMSKTH-UHFFFAOYSA-N 6,8-dibromo-2,3-dihydrochromen-4-one Chemical compound O1CCC(=O)C2=CC(Br)=CC(Br)=C21 NPVIVRRXGMSKTH-UHFFFAOYSA-N 0.000 description 1
- DNNLKHPUJOFTBM-UHFFFAOYSA-N 8-bromo-6-chloro-2,3-dihydro-1h-quinolin-4-one Chemical compound N1CCC(=O)C2=CC(Cl)=CC(Br)=C21 DNNLKHPUJOFTBM-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000423333 Bacteroides fragilis NCTC 9343 Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- HMAXPOJWGWMION-UHFFFAOYSA-N BrC=1C=C(C=C2C(CCNC12)NCCCNC1=CC=C2C(N1)=CCS2)Cl Chemical compound BrC=1C=C(C=C2C(CCNC12)NCCCNC1=CC=C2C(N1)=CCS2)Cl HMAXPOJWGWMION-UHFFFAOYSA-N 0.000 description 1
- VEAADQZXWUFBSA-OAHLLOKOSA-N BrC=1C=C(C=C2[C@@H](CCOC12)NCCCNC1=CC=C2C(N1)=CCS2)Cl Chemical compound BrC=1C=C(C=C2[C@@H](CCOC12)NCCCNC1=CC=C2C(N1)=CCS2)Cl VEAADQZXWUFBSA-OAHLLOKOSA-N 0.000 description 1
- LIYNRADIERQLIN-UHFFFAOYSA-N BrC=1C=C2C(CCNC2=C(C1)Cl)NCCCNC1=CC=C2C(N1)=CCS2 Chemical compound BrC=1C=C2C(CCNC2=C(C1)Cl)NCCCNC1=CC=C2C(N1)=CCS2 LIYNRADIERQLIN-UHFFFAOYSA-N 0.000 description 1
- SYQWLCWPSMUODU-UHFFFAOYSA-N BrC=1C=C2C(CCNC2=C(C1)F)NCCCNC1=CC=C2C(N1)=CCS2 Chemical compound BrC=1C=C2C(CCNC2=C(C1)F)NCCCNC1=CC=C2C(N1)=CCS2 SYQWLCWPSMUODU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000495778 Escherichia faecalis Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000029793 Isoleucine-tRNA ligase Human genes 0.000 description 1
- 101710176147 Isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710149031 Probable isoleucine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000694196 Streptococcus pneumoniae R6 Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021997 Synphilin-1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229940028420 bactroban Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 108010055222 clotting enzyme Proteins 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
[0010]R1は、ハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって場合によって置換される)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルファニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択され;
[0011]Yは、直鎖中に1〜6のメチレン基を有するリンカー基であり、そしてそのうち、1以上のメチレン基が、1以上の(C1−6)アルキル、(C1−6)アルコキシまたは(C1−6)アルキリデニル置換基を有してもよく;
[0012]R2は、ハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって場合によって置換される)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルファニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択され;
[0013]Z1がSである場合、Z2およびZ3はCHであり;Z2がSである場合、Z1およびZ3はCHであり;Z3がSである場合、Z1およびZ2はCHであり;
[0014]Xは、NH、S、SO、SO2、OまたはCH2であり;
[0015]mは、0、または1〜4の整数であり;そして
[0016]nは1、2または3である
の化合物を提供する。
[0018]R3およびR4は、同じ置換基または異なる置換基であってもよく、そして先にR1に関して定義した通りである。好ましい態様において、R3はハロゲンであり、そして最も好ましい態様において、R3は、臭素、塩素、またはヨウ素である。好ましい態様において、R4はハロゲンまたはスルファンであり、そして最も好ましい態様において、R4は、臭素、塩素、ヨウ素またはスルファンである。
[0020]R3およびR4は、同じ置換基または異なる置換基であってもよく、そして先にR1に関して定義した通りである。好ましい態様において、R3はハロゲンであり、そして最も好ましい態様において、R3は、臭素、塩素、またはヨウ素である。好ましい態様において、R4はハロゲンまたはスルファンであり、そして最も好ましい態様において、R4は、臭素、塩素、ヨウ素またはスルファンである。
[0022]R3およびR4は、同じ置換基または異なる置換基であってもよく、そして先にR1に関して定義した通りである。好ましい態様において、R3はハロゲンであり、そして最も好ましい態様において、R3は、臭素、塩素、またはヨウ素である。好ましい態様において、R4はハロゲンまたはスルファンであり、そして最も好ましい態様において、R4は、臭素、塩素、ヨウ素またはスルファンである。
[0087]工程[7]: 5−(3−アセトアミド−プロピルアミノ)−6−カルボキシル−4H−チエノ[3,2−b]ピリジン−7−オン(工程[6]由来の未精製)を6N HCl(200mL)中に懸濁し、そして還流下で16時間加熱した。水性溶液を真空中で蒸発させた後、生じた塩をエタノール/水(85:15、100mL)中に溶解し、そして木炭とともに、還流下で20分間加熱した。次いで、ろ過によって茶色の溶液を得て、そしてこの溶液に酢酸エチル(400mL)を添加して、望ましい産物を沈殿させた。ろ過し、そして酢酸エチルでリンスして、黄褐色固体として、最終純粋産物を得た(23.8g、96%)。5−(3−アミノ−プロピルアミノ)−4H−チエノ[3,2−b]ピリジン−7−オン塩酸塩(XVI)の1H NMR(D2O): 7.77(1Η, d, J=5.6 MHz), 7.14(1H, d, J=5.6 MHz),. 3.35(1H, t. J=6.4 MHz), 3.13(2H, t, J=7.6 MHz), 2.03(2H, m)ppm。
[0088]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0089]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0090]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0091]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0092]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0093]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0094]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0095]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0096]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0097]実施例1に記載する一般的な合成法にしたがって、以下の化合物を調製した。スペクトルデータによって、化合物の同一性を確認する。
[0098]以下の実施例は、実施例13、14および15に示す機能アッセイにおいて有用な、C.ディフィシレMetRSの発現および精製を例示する。
[00101]以下のように、組換えMetRSを用いて、本発明の化合物をアッセイして、酵素MetRSを阻害する能力を決定した:
[00102]反応混合物(1mlあたり)
[00106]本発明の化合物を、C.ディフィシレ増殖を阻害する能力に関してもまたアッセイしてもよい。標準的なアガーに基づくアッセイを用いて、MIC90(C.ディフィシレの90%の増殖を阻害するのに必要な最小阻害濃度)を決定した。
[00109]一団のグラム陽性細菌に対する抗細菌活性に関して、本発明の化合物を試験した。CLSIレファレンス・ブロス微量希釈法を用いて、グラム陽性好気性細菌に対して、化合物を試験した。黄色ブドウ球菌、フェカリス菌、フェシウム菌、化膿性連鎖球菌、表皮ブドウ球菌およびS.ヘモリチクス(S. haemolyticus)に対してデータを得た。試験した化合物は、黄色ブドウ球菌、表皮ブドウ球菌および化膿性連鎖球菌の耐性株を含めて、<0.008〜8μg/mlのMIC範囲で、すべての単離体に対して、強力な抗細菌活性を示した。標準的なCLSI指針アガー希釈法を用いて、ヘリコバクター、ピロリ菌に対してもまたデータを得て、そしてこの結果は、本発明の化合物が、ピロリ菌に対して活性であることを示す。
[00111]動物研究を実行して、C.ディフィシレ感染の治療に関するMetRS阻害剤の効能を決定した。試験したMetRS阻害剤は、5−[3−((R)−6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン(ラセミ混合物およびR鏡像異性体両方)および5−[3−((R)−8−ブロモ−6−クロロ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンであった。2−[3−{3,5−ジブロモ−2−[2−(4−メチル−チアゾール−5−イル)−エトキシ]−ベンジルアミノ}−プロピルアミノ]−1H−キノリン−4−オンもまた試験した。
[00115]C.ディフィシレの病原性は、細胞外毒素AおよびBを産生する能力と関連する。高毒素産生株は、最近の高死亡率の突発の原因である。対照的に、毒素を産生しない単離体は、非病原性である。毒素産生は、活性タンパク質合成を必要とするため、タンパク質合成機構の阻害は、新規毒素産生を抑制すると予期される。したがって、in vitroのC.ディフィシレ毒素産生に対する影響に関して、MetRS阻害剤を評価した。
[00116]C.ディフィシレ株ATCC43255をCDC嫌気性菌アガー(Remel、カンザス州レネクサ)上で嫌気的に増殖させ、そして維持した。増殖に対する抗細菌剤の影響を試験するため、106CFU/mLの最初の接種物を用いて、96ウェル・ブレイン・ハート・インフュージョン(BHI)ブロス培養中で35℃で40時間、細胞を嫌気的に増殖させた。C.ディフィシレ細胞が高密度の際の、毒素産生に対する抗細菌剤の影響を試験するため、96ウェル・ブレイン・ハート・インフュージョン(BHI)ブロス培養中で35℃で24時間、細胞を嫌気的に増殖させた。次いで、消費した培地を、0.015〜16μg/mLの濃度範囲でMetRS阻害剤および対照剤を含有する新鮮なブロスと交換した。4日後、595nmでの光学密度測定によって、そしてCDC嫌気性菌アガー上での培養によって、それぞれ、増殖および細胞生存度を監視した。培養上清を収集し、そして抗毒素Aモノクローナル抗体(Novus Biologicals、コロラド州センテニアル)を用いたELIFA(酵素連結免疫フローアッセイ)によって毒素Aを検出した。
[00117]MetRS阻害剤、5−[3−(6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンおよび5−[3−{3,5−ジブロモ−2−[2−(4−メチル−チアゾール−5−イル)−エトキシ]−ベンジルアミノ}−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンは、ブロス中、0.25μg/mL以上の濃度で、C.ディフィシレの増殖を防止した。
[00119]MetRS阻害剤は、ブロス培養中、C.ディフィシレの増殖および毒素産生の両方に阻害効果を示す。さらに、毒素産生は、静止期培養中で、効果的に遮断された。静菌性のMetRS阻害剤による毒素産生のこの抑制の結果として、C.ディフィシレは、本質的に非毒素産生性となり、そしてしたがって非病原性となる。この効果は、その作用様式が、細菌が活発に増殖することを必要としない、MetRS阻害剤などの、タンパク質合成阻害剤に特有である。
[00120]C.ディフィシレは、加熱、乾燥、および殺菌剤などの多くの洗浄剤に耐性である胞子を形成する能力に関してよく知られている生物である。環境中に存在する胞子は、疾患を引き起こす生物の貯蔵庫として働きうる。C.ディフィシレ感染は、しばしば、胞子の摂取によって開始され、この胞子が、GI管で出芽してCDADを引き起こす。CDAD治療後、腸に胞子が保持されることもまた、再発疾患の主な原因であると考えられる。C.ディフィシレが胞子を産生する能力または胞子の出芽が減少すると、この疾患の治療の重要な前進に相当しうる。胞子コートは、主にタンパク質で構成され、胞子コートの生成にはタンパク質合成が必要であり、そして活性タンパク質合成の阻害は、この生物において、胞子産生に影響を及ぼすと予期される。したがって、in vitroのC.ディフィシレ胞子産生に対するその影響に関して、MetRS阻害剤を評価した。
[00121]BI/NAP1遺伝子型に属する、2つの最近の突発単離体を含む、C.ディフィシレの4つの臨床単離体の胞子形成に対する影響に関して、MetRS阻害剤を評価した。C.ディフィシレ株を補充Brucella血上で24〜48時間増殖させ、そしてコロニーを生理食塩水中に懸濁して、0.5 McFarland標準と等しい濁度を達成した。0.06〜2μg/mLの範囲の濃度でMetRS阻害剤を含有する5%ヒツジ溶解血を含む、新鮮な補充Brucellaアガープレート表面上に、C.ディフィシレ懸濁物(10μL)をスプレッドし、そして35℃で96時間、嫌気的にインキュベーションした。MetRS含有プレートに接種するのに用いたものと同じ細胞懸濁物のアリコットを、生菌数用にもまたプレーティングし、そしてさらに250μLアリコットを、250μLの無水エタノールで、室温で1時間処理して、植物性(vegetative)細胞を除去し、そして胞子を数えることを可能にした。化合物の存在下で96時間インキュベーションした後の4つのすべての株に関して、胞子対総細胞の比を再び決定し、そしてこれを用いて、胞子形成率に対する薬剤不含対照とMetRS阻害剤の効果を比較した。
[00122]4つのC.ディフィシレ株のうち3つが、測定可能な数の胞子を産生し、そしてこれらを上述のように評価した。5−[3−((R)−6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンですべての株を処理すると、すべての株において、0.25xMIC(<2%胞子)および0.5xMIC(<1%胞子)で、胞子産生の減少が示された。これは、メトロニダゾールでの処理後に得た結果とは顕著に対照的であり、メトロニダゾールの場合、試験したすべての株は、薬剤のMIC濃度未満に曝露した後、胞子産生の顕著な増加(100%までの胞子)を示す。バンコマイシンでの処理は、2つの株では類似の胞子産生増加を誘導したが、1つの株では誘導せず、この株では胞子数は低いままであった。
[00123]MIC未満(0.25および0.5xMIC)の5−[3−((R)−6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンは、C.ディフィシレの植物性細胞が胞子を形成するのを防止する際に有効であった。これらのデータは、5−[3−((R)−6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オンが、突発を防止し、そして環境におけるC.ディフィシレ胞子の広い蔓延と相関づけられている再発率を減少させる際に有用な役割を有する可能性もあることを示唆する。
Claims (8)
- 式(I):
R1は、ハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって置換されていてもよい)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルフィニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択され;
Yは、直鎖中に1〜6のメチレン基を有するリンカー基であり、そしてそのうち、1以上のメチレン基が、1以上の(C1−6)アルキル、(C1−6)アルコキシまたは(C1−6)アルキリデニル置換基を有してもよく;
R2は、ハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって置換されていてもよい)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルフィニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択され;
Z1がSである場合、Z2およびZ3はCHであり;Z2がSである場合、Z1およびZ3はCHであり;Z3がSである場合、Z1およびZ2はCHであり;
Xは、NH、S、SO、SO2、O、またはCH2であり;
nは1、2または3であり;そして
mは、0、または1〜4の整数である
の化合物。 - 式(II):
R3およびR4は、同じ置換基または異なる置換基であってもよく、そしてハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって置換されていてもよい)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルフィニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択される
を有する請求項1の化合物。 - 式(III):
R3およびR4は、同じ置換基または異なる置換基であってもよく、そしてハロ、シアノ、ヒドロキシル、(C1−6)アルキル(ハロ、ヒドロキシル、アミノ、モノからペルフルオロ(C1−3)アルキル、カルボキシ、または(C1−6)アルコキシカルボニルによって置換されていてもよい)、(C3−7)シクロアルキル、(C1−6)アルコキシ、アミノ、モノまたはジ−(C1−6)アルキルアミノ、アシルアミノ、カルボキシ、(C1−6)アルコキシカルボニル、カルボキシ(C1−6)アルキルオキシ、(C1−6)アルキルチオ、(C1−6)アルキルスルフィニル、(C1−6)アルキルスルホニル、スルファモイル、モノおよびジ−(C1−6)アルキルスルファモイル、カルバモイル、モノおよびジ−(C1−6)アルキルカルバモイル、ならびにヘテロシクリルより選択される
を有する請求項1の化合物。 - 請求項1の化合物の塩。
- 薬学的に許容されうる塩である、請求項4の塩。
- 5−[3−(6,8−ジブロモ−l,2,3,4−テトラヒドロ−キノリン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(6,8−ジブロモ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(8−ブロモ−6−クロロ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(6−クロロ−8−ヨード−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(6−ブロモ−8−クロロ−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(6−ブロモ−8−クロロ−l,2,3,4−テトラヒドロ−キノリン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(8−ブロモ−6−クロロ−l,2,3,4−テトラヒドロ−キノリン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;
5−[3−(8−ブロモ−6−メチルスルファニル−クロマン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン;および
5−[3−(6−ブロモ−8−フルオロ−l,2,3,4−テトラヒドロ−キノリン−4−イルアミノ)−プロピルアミノ]−4H−チエノ[3,2−b]ピリジン−7−オン
より選択される、請求項1に記載の式(I)の化合物。 - 薬学的に許容されうるキャリアーまたは賦形剤と一緒に、抗細菌的に有効な量の請求項1記載の化合物を含む、薬学的組成物。
- 細菌感染の治療に用いる、請求項1に記載の式(I)の化合物を含有する薬学的組成物であって、
前記化合物は、治療の必要がある患者に、抗細菌的に有効な量で投与される、前記薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82694506P | 2006-09-26 | 2006-09-26 | |
US60/826,945 | 2006-09-26 | ||
PCT/US2007/078124 WO2008039639A2 (en) | 2006-09-26 | 2007-09-11 | Substituted thienopyridone compounds with antibacterial activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010504985A JP2010504985A (ja) | 2010-02-18 |
JP5247705B2 true JP5247705B2 (ja) | 2013-07-24 |
Family
ID=39230857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009530510A Active JP5247705B2 (ja) | 2006-09-26 | 2007-09-11 | 抗細菌活性を持つ置換チエノピリドン化合物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2094714B1 (ja) |
JP (1) | JP5247705B2 (ja) |
ES (1) | ES2392897T3 (ja) |
WO (1) | WO2008039639A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973050B2 (en) | 2006-09-26 | 2011-07-05 | Crestone, Inc. | Enantiomeric compounds with antibacterial activity |
US7994192B2 (en) | 2006-09-26 | 2011-08-09 | Crestone, Inc. | Substituted thienopyridone compounds with antibacterial activity |
US8697720B2 (en) | 2006-09-26 | 2014-04-15 | Crestone, Inc. | Substituted phenylether-thienopyridone compounds with antibacterial activity |
CN101652140B (zh) * | 2006-09-26 | 2013-07-10 | 克莱斯通公司 | 具有抗菌活性的对映体化合物 |
US8658670B2 (en) | 2006-09-26 | 2014-02-25 | Crestone, Inc. | Methods and compounds for treatment of clostridium based infection |
AR082472A1 (es) * | 2010-08-04 | 2012-12-12 | Janssen Pharmaceutica Nv | Compuestos con actividad antibacteriana contra clostridium |
CN115974833A (zh) * | 2022-12-28 | 2023-04-18 | 苏州汉德创宏生化科技有限公司 | 一种3-氨基噻吩草酸盐的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8515207D0 (en) * | 1985-06-15 | 1985-07-17 | Boots Co Plc | Therapeutic agents |
CN1307565A (zh) * | 1998-04-29 | 2001-08-08 | 史密丝克莱恩比彻姆有限公司 | 用作mrs抑制剂和杀菌剂的喹诺酮化合物 |
GB9822241D0 (en) * | 1998-10-12 | 1998-12-09 | Smithkline Beecham Plc | Novel compounds |
EP1619947A4 (en) * | 2003-05-01 | 2006-05-31 | Replidyne Inc | ANTIBACTERIAL COMPOSITIONS AND ASSOCIATED METHODS |
CN101652140B (zh) * | 2006-09-26 | 2013-07-10 | 克莱斯通公司 | 具有抗菌活性的对映体化合物 |
-
2007
- 2007-09-11 ES ES07842226T patent/ES2392897T3/es active Active
- 2007-09-11 WO PCT/US2007/078124 patent/WO2008039639A2/en active Application Filing
- 2007-09-11 EP EP07842226A patent/EP2094714B1/en active Active
- 2007-09-11 JP JP2009530510A patent/JP5247705B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2008039639A3 (en) | 2008-06-12 |
WO2008039639A2 (en) | 2008-04-03 |
ES2392897T3 (es) | 2012-12-14 |
EP2094714A2 (en) | 2009-09-02 |
EP2094714A4 (en) | 2011-04-20 |
JP2010504985A (ja) | 2010-02-18 |
EP2094714B1 (en) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5247705B2 (ja) | 抗細菌活性を持つ置換チエノピリドン化合物 | |
JP5247706B2 (ja) | 抗細菌活性を持つ鏡像異性化合物 | |
KR101337237B1 (ko) | 항균제로서의 퀴놀린 유도체 | |
NO340352B1 (no) | Kinolinderivater som antibakterielle midler | |
CA2824403C (en) | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea | |
WO2008039642A2 (en) | Methods and compounds for treatment of clostridium based infection | |
JP4819980B2 (ja) | 細菌性腸管疾患の治療のための5−ヒドロキシメチル−オキサゾリジン−2−オン誘導体 | |
US7994192B2 (en) | Substituted thienopyridone compounds with antibacterial activity | |
US20070213362A1 (en) | 2-nh-heteroarylimidazoles with antibacterial activity | |
WO2008039641A2 (en) | Substituted phenylether-thienopyridone compounds with antibacterial activity | |
KR101329587B1 (ko) | 항균제로서의 퀴놀린 유도체 | |
KR101413094B1 (ko) | 항박테리아제로서의 퀴놀린 유도체 | |
US7973050B2 (en) | Enantiomeric compounds with antibacterial activity | |
US8697720B2 (en) | Substituted phenylether-thienopyridone compounds with antibacterial activity | |
US20060287360A1 (en) | Novel compounds | |
US7030137B2 (en) | Substituted thiophenes with antibacterial activity | |
JP2006519261A (ja) | 抗菌活性を有する置換されたチオフェン | |
JP2004137185A (ja) | チオフェン骨格を有する抗菌剤 | |
WO2023148767A1 (en) | 1 h-pyrazolo[4,3-d]pyrimidine derivatives as staphylococcus aureus inhibitors | |
WO1993020072A1 (en) | (furan-2-yl)-2-(1-normon-2-yl) oxazole derivatives with antibacterial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130218 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5247705 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160419 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |